MassBio is proud to present the 2025 Lundbeck External Innovation Event (September 22, 2025 | MassBioHub, Cambridge, MA). Join us for an inspiring afternoon of meaningful dialogue and connection, focused on strengthening collaboration between Lundbeck and the US biotech community.
What to expect: The event offers a chance to explore shared innovation priorities, scientific focus areas, and partnership opportunities as Lundbeck looks to advance innovation in neuroscience together. At this exclusive event, you will gain insights into:
- Lundbeck’s R&D and Neuroscience focus
- External Research & Innovation strategy
- Specific Research opportunities of Lundbeck’s interest within Neuroscience and Drug Discovery
- Insight into collaboration models from early-stage research to in-licensing opportunities and examples of how Lundbeck works with external partners
Following the presentations and panel discussions, stay for a networking reception where you can speak one-on-one with Lundbeck’s team of innovators. If you would like to meet Lundbeck for a personal dialog, please contact Agne Valentin, Director of Strategy & Operations.
Who you’ll hear from:
- Johan Luthman, Executive Vice President, Head of Research & Development
- Tarek Samad, Senior Vice President, Global Head of Research and Corporate Patents & Trademarks
- Klaus Simonsen, Vice President, Head of External Research & Innovation
- Morten Grunnet, Vice President, Neuroscience
What they’re saying: “At Lundbeck, we are harnessing both internal and external innovation to advance our pipeline as a Focused Innovator,” said Tarek Samad, Senior Vice President, Global Head of Research and Corporate Patents & Trademarks. “Our newly established External Research & Innovation Unit is central to this journey, and we are enthusiastic about exploring mutually beneficial partnerships to bring new medicines to patients.”
What we’re saying: “MassBio is all about facilitating connections and inspiring partnerships that advance patient-driven drug development,” said Jason Cordeiro, MassBio’s Chief Operating and Innovation Officer. “This is an exclusive opportunity to go deeper into Lundbeck’s R&D, neuroscience innovation, and partnering strategy, and explore the Danish biopharma company’s approach to collaboration.”
About Lundbeck: Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.
- As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.
- We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.